The original success of Sildenafil undeniably revolutionized the pharmaceutical landscape, but placing funds in companies heavily reliant on off-patent versions presents a complex picture. Although early earnings were impressive, the expiration of patents and the rise of discounted alternatives have diminished sales. Thus, a thorough assessment of